Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Journal of Pharmacokinetics and Biopharmaceutics

Search In Journal Title:

Abbravation: Journal of Pharmacokinetics and Biopharmaceutics

Search In Journal Abbravation:

Publisher

Kluwer Academic Publishers-Plenum Publishers

Search In Publisher:

DOI

10.1007/bf03019872

Search In DOI:

ISSN

0090-466X

Search In ISSN:
Search In Title Of Papers:

Pharmacokinetics of teicoplanin in man after intra

Authors: Gian Luigi Traina Maurizio Bonati
Publish Date: 1984/04/01
Volume: 12, Issue: 2, Pages: 119-128
PDF Link

Abstract

The pharmacokinetics of teicoplanin a new glycopeptide antibiotic active against grampositive aerobic and anaerobic bacteria was studied in adult male volunteers given 2 and 3 mg/ kg doses by a constantrate 05hr infusion Serum and urine samples were collected up to 96 hr Mean peak serum levels after the two doses were 157 and 224 μg/ml Postinfusion serum teicoplanin levels showed triexponential decay A threecompartment body model gave close values for pharmacokinetic parameters after the two doses The mean halflife of the λ1 phase was 203 min that of the λ2 phase was 29 hr and the halflife of the estimated λ3 phase was 405 hr in good agreement with that of the λZ phase 459 hr calculated from the last urine data The mean volume of distribution of the central compartment was 009 liter/kg and the steadystate volume of distribution using noncompartmental analysis was 084 liter/kg Total clearance averaged 1605 ml/hr/kg with renal clearance arbout half this 951 ml/hr/kg calculated by two different methods The average total recovery of active teicoplanin in urine over 4 days was 52 suggesting that both renal and nonrenal mechanisms are involved in elimination of the drug The concentrations of teicoplanin in serum and urine exceeded the MIC ranging from 002 to 2 μg/ml on many pathogenic organisms for at least 1 day after administration


Keywords:

References


.
Search In Abstract Of Papers:
Other Papers In This Journal:

  1. Influence of plasma protein binding kinetics on hepatic clearance assessed from a “tube” model and a “well-stirred” model
  2. Quinidine pharmacokinetics in man: Choice of a disposition model and absolute bioavailability studies
  3. Effect of plasma protein and tissue binding on the time course of drug concentration in plasma
  4. A nonlinear mixed-effects pharmacokinetic model comparing two formulations of cyclosporine in stable renal transplant patients
  5. Linear pharmacokinetic models: Geometric construction to determine transfer and elimination rate constants
  6. Modeling of drug response in individual subjects
  7. Prediction of diazepam disposition in the rat and man by a physiologically based pharmacokinetic model
  8. Pharmacokinetics of piroxicam, a new nonsteroidal anti-inflammatory agent, under fasting and postprandial states in man
  9. Pharmacokinetics and bioavailability of intravenous, oral, and rectal nitrazepam in humans
  10. Application of optimal sampling theory to the determination of metacycline pharmacokinetic parameters: Effect of model misspecification
  11. Estimation of drug binding parameters
  12. Relationship between plasma or serum drug concentration and amount of drug in the body at steady state upon multiple dosing
  13. Theoretical considerations in the calculation of bioavailability of drugs exhibiting Michaelis-Menten elimination kinetics
  14. Mathematical model for in vivo pharmacodynamics integrating fluctuation of the response: Application to the prolactin suppressant effect of the dopaminomimetic drug DCN 203–922
  15. Mathematical model for in vivo pharmacodynamics integrating fluctuation of the response: Application to the prolactin suppressant effect of the dopaminomimetic drug DCN 203–922
  16. Simulation for population analysis of Michaelis-Menten elimination kinetics
  17. Pharmacodynamic modeling of the in vitro vasodilating effects of organic mononitrates

Search Result: